Residents

Poseida

Poseida

Poseida Therapeutics, Inc is currently developing CAR-T and gene therapy products for cancer and orphan diseases. Spinout of Transposagen Biopharmaceuticals early this year, Poseida is also collaborating with J&J’s Janssen to develop allogeneic CAR-T therapies against cancer. Poseida boasts best-in-class genome engineering capabilities for effectively silencing target genes or inserting therapeutic genes and/or technologies. Proprietary tools include piggyBac™ DNA Modification System, NextGEN™ CRISPR, XTN™ TALEN and Footprint-Free™ Gene Editing System, which are clean (synthetic and virus-free) and can be surgically precise. Poseida aims to shuttle the first CAR-T and gene therapy product candidates into Phase I clinical trials in early 2016.

Area of focus: 
Oncology
Graduation date: 
03/25/2017
Commencement date: 
04/01/2015

Share